Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 13 of 13 publications.

Hamadani M, Spira AI, Zhou X, Liao L, Chen L, Radford J, Ai WZ, Solh MM, Ardeshna KM, Hess BT, Caimi PF, Stathis A, Carlo Stella C, Alderuccio JP, Kahl BS, Wang Y, Qin YG, Xu ZC, Zinzani PL. Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial. Blood Adv. 2024 Jan;9(1):93-8. doi: 10.1182/bloodadvances.2023010636

Wolf J, Souquet PJ, Goto K, Cortot A, Baik C, Heist R, Kim TM, Han JY, Neal JW, Mansfield AS, Gilloteau I, Nwama N, Waldron-Lynch M, Davis KL, Giovannini M, Awad MM. Improved survival outcomes in patients with MET-dysregulated advanced NSCLC treated with MET inhibitors: results of a multinational retrospective chart review. Clin Lung Cancer. 2023 Nov;24(7):641-650.e. doi: 10.1016/j.cllc.2023.08.011

Salles G, Schuster SJ, Dreyling M, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith SM, Jimenez-Ubieto A, Davis KL, Anjos C, Chu J, Zhang J, Lobetti Bodoni C, Thieblemont C, Fowler NH, Dickinson M, Martinez-Lopez J, Wang Y, Link BK. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. Blood Adv. 2022 Nov 22;6(22):5835-43. doi: 10.1182/bloodadvances.2022008150

Mansfield C, Masaquel A, Sutphin J, Weiss E, Gutierrez M, Wilson J, Boeri M, Li J, Reyes C. Patients' priorities in selecting chronic lymphocytic leukemia treatments. Blood Adv. 2017 Nov 14;1(24):2176-85. doi: 10.1182/bloodadvances.2017007294

Morelli X, Foraster M, Aguilera I, Basagana X, Corradi E, Deltell A, Ducret-Stich R, Phuleria H, Ragettli MS, Rivera M, Thomasson A, Kunzli N, Slama R. Short-term associations between traffic-related noise, particle number and traffic flow in three European citie. Atmos Environ. 2015 Feb;103:25-33. doi: 10.1016/j.atmosenv.2014.12.012

Ragettli MS, Ducret-Stich RE, Foraster M, Morelli X, Aguilera I, Basagana X, Corradi E, Ineichen A, Tsai M, Probst-Hensch N, Rivera M, Slama R, Kunzli N, Phuleria HC. Spatio-temporal variation of urban ultrafine particle number concentrations. Atmos Environ. 2014 Oct;96:275-83. doi: 10.1016/j.atmosenv.2014.07.049

Luciano JV, Barrada JR, Aguado J, Osma J, García-Campayo J. Bifactor analysis and construct validity of the HADS: a cross-sectional and longitudinal study in fibromyalgia patients. Psychological Assessment. 2014 Jun;26(2):395-406.

Aguilera I, Basagana X, Pay MT, Agis D, Bouso L, Foraster M, Rivera M, Baldasano JM, Kunzli N. Evaluation of the CALIOPE air quality forecasting system for epidemiological research: the example of NO2 in the province of Girona (Spain). Atmos Environ. 2013 Jun;72:134-41. doi: 10.1016/j.atmosenv.2013.02.035

Du XL, Parikh RC, Lairson DR, Giordano SH, Cen P. Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer. Med Oncol. 2013 Mar;30(1):440. doi: 10.1007/s12032-012-0440-4

Codony-Servat J, Garcia-Albeniz X, Pericay C, Alonso V, Escudero P, Fernandez-Martos C, Gallego R, Martinez-Cardus A, Martinez-Balibrea E, Maurel J. Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer. Med Oncol. 2013 Mar;30(1):428. doi: 10.1007/s12032-012-0428-0

Rivera M, Basagana X, Aguilera I, Agis D, Bouso L, Foraster M, Medina-Ramon M, Pey J, Kunzli N, Hoek G. Spatial distribution of ultrafine particles in urban settings: a land use regression model. Atmos Environ. 2012 Jul;54:657-66. doi: 10.1016/j.atmosenv.2012.01.058

Basagana X, Rivera M, Aguilera I, Agis D, Bouso L, Elosua R, Foraster M, de Nazelle A, Nieuwenhuijsen M, Vila J, Kunzli N. Effect of the number of measurement sites on land use regression models in estimating local air pollution. Atmos Environ. 2012 Jul;54:634-42. doi: 10.1016/j.atmosenv.2012.01.064

Soni MK, Cella D, Masters GA, Burch SP, Heyes AE, Silberman C. The validity and clinical utility of symptom monitoring in advanced lung cancer: a literature review. Clin Lung Cancer. 2002 Nov;4(3):153-60.